--- title: "Absci cash rises to $201 million after June raise" url: "https://aibio.space/news/absci-cash-rises-201-million-after-june-raise-lilly-invests-40-million/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-08-11" section: "Financings" tickers: "NASDAQ:ABSI" source: "https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial" summary: "The company extended its runway into the second half of 2028. Lilly's stake carries no rights to the ABS-201 antibody." --- By the aibio.space Absci desk. Sources - [Absci](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial) - [Absci offering release](https://investors.absci.com/news-releases/news-release-details/absci-announces-pricing-100-million-underwritten-offering) - [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07317544) [ABSI](https://aibio.space/companies/absci/) 2026-08-11 # Absci cash rises to $201 million after June raise; Lilly invests $40 million Tickers [ABSI](https://aibio.space/companies/absci/) The company extended its runway into the second half of 2028. Lilly's stake carries no rights to the ABS-201 antibody. ## Key facts - **Company**: Absci Corporation (NASDAQ: ABSI) - **News type**: Financings - **Primary source**: [Absci](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial) *A distant skyline over open water. Photo: Matt Bango, CC0, via StockSnap. The picture shows the field, not the companies named.* Absci reported a [second-quarter 2026 net loss of $33.2 million](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial) on Aug. 11, up from $30.6 million a year earlier, and said a June stock sale lifted cash, cash equivalents and marketable securities to $201.1 million at June 30, from $125.7 million at March 31. The company now expects its cash to fund operations into the second half of 2028. In May it had guided to the [first half of 2028](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-first-quarter-2026-financial). The balance includes $93.6 million in net proceeds from the June offering, [Absci said](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial). ## The details Revenue from partner programs was $0.3 million, against $0.6 million in the second quarter of 2025. Research and development expense rose to $22.6 million from $20.5 million, and selling, general and administrative expense rose to $9.2 million from $8.5 million, [per the release](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial). For the first six months, the net loss was $62.8 million. Eli Lilly made a $40 million strategic equity investment, Absci said. The collaboration is tailored to ABS-201's clinical development and gives Lilly no rights to the program. A Lilly representative joined Absci's endometriosis advisory board. The [June offering release](https://investors.absci.com/news-releases/news-release-details/absci-announces-pricing-100-million-underwritten-offering) lists Lilly among the buyers, alongside Adage, BVF Partners, Columbia Threadneedle, Invus and Redmile. Absci also [listed ABS-202](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial), a preclinical PRLR antibody for an undisclosed inflammation and immunology indication. ## Context ABS-201, an antibody against the prolactin receptor, is in the phase 1/2a [HEADLINE trial](https://clinicaltrials.gov/study/NCT07317544) in Australia, which plans to enroll 227 participants. Single-dose data in June showed no serious adverse events in 32 healthy adults and an estimated half-life of at least 65 days, which Absci said could support two or three doses over six months, [according to the company](https://investors.absci.com/news-releases/news-release-details/absci-announces-positive-interim-phase-1-data-headlinetm-trial). Founder and CEO Sean McClain said interim results "have the potential to demonstrate ABS-201's regenerative mechanism," [per the release](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial). In May he called the drug a candidate to be "the first new mechanism of action in androgenetic alopecia in nearly three decades," [Absci said](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-first-quarter-2026-financial). ## What it means for investors The quarter was about funding, not operations. Spending is rising as ABS-201 moves through the clinic, and [revenue from partner programs](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial) has dropped to a few hundred thousand dollars a quarter. The June raise more than covers the gap for now. At a quarterly loss near $33 million, $201 million lasts well past the hair loss readouts. The Lilly investment matters more as a signal than as cash. A large drugmaker putting [$40 million into the stock without taking program rights](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial) suggests outside interest in the PRLR approach. It does not guarantee a later deal. The risk is concentration: Absci's value now rests mostly on one antibody in two indications, and the hair loss efficacy question has not been answered. ## What to watch Interim proof-of-concept data from HEADLINE in pattern hair loss are due in the [second half of 2026](https://investors.absci.com/news-releases/news-release-details/absci-reports-business-updates-and-second-quarter-2026-financial), with the full 26-week readout in early 2027. Absci has since moved its endometriosis phase 2 start to [mid-2027](https://investors.absci.com/news-releases/news-release-details/absci-announces-preliminary-details-phase-2-storylinetm-trial-ai). [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story ABSI Absci Corporation NASDAQ ยท United States Open the desk ## More from the Absci desk Financings ### [Absci raises $100 million at $7.41 a share with Eli Lilly among buyers](https://aibio.space/news/absci-raises-100-million-7-41-share-eli-lilly-among-buyers/) Jun 24, 2026 Mergers ### [Absci and Totient sellers agree final milestone payout under 2021 merger agreement](https://aibio.space/news/absci-totient-sellers-agree-final-milestone-payout-under-2021-merger/) Nov 4, 2025 Debt Financing ### [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/) Oct 30, 2026 --- Source page: https://aibio.space/news/absci-cash-rises-201-million-after-june-raise-lilly-invests-40-million/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Absci cash rises to $201 million after June raise", 2026-08-11, https://aibio.space/news/absci-cash-rises-201-million-after-june-raise-lilly-invests-40-million/